ภารกิจกู้น้องสาว เคลียร์ปัญหาคิดไม่ตกของจุดซ่อนเร้น

อย่าเพิ่งตกใจ กระชับพื้นที่วันนี้ ไม่เกี่ยวกับรถถัง ทหาร การเมือง แต่ประการใด แต่เป็นเรื่องลับเฉพาะของผู้หญิง ที่น้องสาวสูญเสียความสาวและความสวยไปตามวัย หรือน้องสาวไม่สวยตั้งแต่แรกเกิด จนเสียความมั่นใจ เทคโนโลยีการกู้วิกฤตน้องสาวในวันนี้ อาจเป็นทางออกที่สาวรุ่นใหญ่และแรกรุ่นค้นหามานาน

Stefano Salvatore

Consideramos SmartXide2 un instrumento versátil e insustituible para las aplicaciones de regeneración de la mucosa vaginal, con el tratamiento llamado MonaLisa Touch® y para la cirugía genital ambulatoria. El sistema se ha convertido en particularmente eficaz, garantizando resultados siempre excelentes y con la máxima comodidad para mis pacientes.”

Japan – MonaLisa Touch® presentation to mark the 5th anniversary of DEKA Japan

On the occasion of the 5th anniversary of DEKA Japan – DEKA’s subsidiary in Japan – the MonaLisa Touch® procedure was presented to over 150 physicians.
The event was held at the Italian embassy in Tokyo, one of the city’s most important diplomatic buildings, representing the close ties between Japanese and Italian culture.
The event was chaired by Ambassador Domenico Giorgi, who gave a warm welcome to the many guests and invited Dr. Mauro Galli (DEKA International Sales Director) to present the company. Mauro Galli recounted the history of DEKA, from its origins to its latest innovation: MonaLisa Touch®
The presentation ended with a speech by Gabriele Clementi (Chairman of the El.En. group) who delivered a message of congratulations to DEKA Japan, a key partner for DEKA.
The participants were also honored by a visit from the Japanese Minister of Health Yasuhisa Shiozaki, who wished DEKA Japan every success.

MonaLisa Touch® launch in China highly successful

MonaLisa Touch®, the innovative system of vaginal rejuvenation that is proving such a hit in many countries, including Italy and the United States, was presented last December 10 to the specialist press and to the industry in the Republic of China.

From Italy a Special Preview, as the event held at and in conjunction with the Italian Embassy in Beijing was called, was attended by various members of the medical sector, directors of hospitals and private clinics and the specialist press. Guests included representatives from major Chinese search engines and some of the most popular local blogs.

The event began with greetings from Italian Ambassador Alberto Bradanini who expressed his hope for greater and more active collaboration between Italy and China in the medical field. There were a number of speakers: Mauro Galli (DEKA International Sales Director) presented the El.En. Group, the group holding company to which DEKA belongs, Riccardo Stocchi, China Sales Manager, presented DEKA and MonaLisa Touch® illustrating the market opportunities and finally Prof. Nicola Zerbinati, of Varese University, explained the treatment from a clinical point of view and the background scientific studies that make MonaLisa Touch® the only scientifically validated method.

They were followed by the testimony of Prof. Yang (Head of the Dermatology Department at Beijing Hospital) and Prof. Gao Zhiqiang (Surgical Division Director at the Union Hospital in Beijing) who spoke of the reliability and professionalism both of DEKA and the SmartXide2 system which has been used for surgical applications.

“We have great expectations for China, which is for us a very strategic market”, said Mauro Galli (DEKA International Sales Director). We hope that a significant and fruitful partnership will be born.” 

DEKA has a unique product, with no similar competitor in a market that is looking for total well-being. The wellness market is actually growing in China and MonaLisa Touch® is a perfect fit in this context.

Our motto is to act step by step, especially in difficult new markets such as China, went on Mauro Galli. We will assess reactions to this event, and if all goes to plan, we may repeat the presentation in other cities such as Shanghai, for example. China is indeed great and Beijing is only one part of it! ”

From the point of view of distribution, we have reached agreements with some companies with connections in both the public and private sectors. Our goal is in fact to reach hospitals and medical SPAs – private clinics which are growing strongly in China”. As Riccardo Stocchi (China Export Manager) says “We have also established partnerships with hospitals in Beijing, Shanghai and Chengdu, which are conducting clinical trials on the treatment of vaginal laxity, both after childbirth and in menopause, with MonaLisa Touch®.”

China is an important strategic goal for DEKA and the event marks a first step towards a role that we imagine will continue to grow. The benefits that the MonaLisa Touch® treatment can bring this country is a concrete contribution and a significant innovation for the welfare of Chinese women.

MonaLisa Touch® arrives in the US

DEKA announces that Cynosure Inc. (Chemsford, MA, USA) will distribute in USA and Canada the CO2 laser systemSmartXide2 for V2LR applications (MonaLisa Touch®) under the brand name of DEKA. Cynsoure has introduced SmartXide2 for the first time in USA at PAGS 2014 (Pelvic Anatomy and Gynecology Surgery) from December 4th to 6th in Las Vegas. “This agreement is an important step for millions of North America women who will benefit of this important treatment for the side effects of vaginal atrophy. We are sure that Cynosure is the right distributor because they know very well the potentiality and reliability of CO2 laser system designed by DEKA.” Commented Prof. Leonardo Masotti, President of DEKA. Cynosure is already taking many orders from US doctors and will install the first systems in few weeks. “Introducing MonaLisa Touch® in USA and Canada is very important for DEKA and all DEKA distributors. I’m sure that MonaLisa Touch® will be successful also in increasing the acceptance of this innovative and new technique all over the World.” Said Mauro Galli, Export Manager of DEKA, “DEKA has already installed more than 600 SmartXide2 systems all over the world and MonaLisa Touch® treatments are estimated to be already more than 300,000. No important adverse effects have been reported until now, placing MonaLIsa Touch® as the surest and safest laser treatment known.”   DEKA believes all the MonaLisa Touch® distributors will boost their sales thank to the enormous clinical and commercial advertising going to come from the US market in the following months and will require them to duplicate their efforts to increase sales of MonaLisa Touch® in their territories.

1 2 3 … 5